Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction
NCT ID: NCT01414452
Last Updated: 2015-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
2011-04-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants
NCT00308633
Diagnostics for the Reperfusion Injury Following MI
NCT00529607
Role of Epicardial Adipose Tissue in Coronary Artery Disease
NCT00279227
Coronary Collaterals and Post-reperfusion Intramyocardial Hemorrhage
NCT05898425
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
NCT01618123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STEMI patients
Patients with ST elevation myocardial infarction,lasting \<12 hour, who were succesfully treated with primary PCI
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* use of immunosuppressive therapy
* unsuccessful recanalisation
* not-interpretable ST-T segment
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universiteit Antwerpen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
M Claeys
Prof dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Claeys, MD PHD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Antwerp
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital
Edegem, Antwerp, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UAntwerpen
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.